President Trump announced Friday that all 50 states, Washington, D.C., and Puerto Rico will participate in the GENEROUS model to offer lower drug prices to Medicaid programs. The move is a major component of his plan to lower drug prices.
More than two dozen pharma companies agreed to sell drugs to state Medicaid programs at prices available in peer countries under GENEROUS. The administration says the model is intended to give lower drug prices to Medicaid programs.
The GENEROUS Model Explained
The GENEROUS model is intended to give lower drug prices to Medicaid programs. It works by having pharma companies agree to sell their drugs at prices available in peer countries.
Trump made the announcement Friday, saying the model would help states get cheaper drugs for their Medicaid programs. The program covers low-income Americans.
Who Agreed to the Deals
More than two dozen pharma companies signed on to the model. The administration did not name all of them in the announcement.
The companies agreed to sell drugs to state Medicaid programs at prices available in peer countries.
What the Announcement Skipped
The reporting notes that the announcement left many questions unanswered, including how much Medicaid recipients would save. The administration did not say how much money states or patients would actually see in their pockets.
The administration framed the model as a way to lower drug prices, but it did not provide the numbers that would show whether that promise holds up.
Why the Deal Matters
The deal is a major component of Trump’s plan to lower drug prices. Medicaid covers a large share of low-income Americans.
By securing commitments from multiple pharma companies, the administration hopes to reduce the cost of prescription drugs for millions of Medicaid recipients.
What Comes Next
The announcement Friday was the first step. The states now need to implement the model and negotiate with pharma companies.
Whether the model delivers on its promise of lower drug prices will depend on how it is carried out.
The proof will come when the prices are compared to those in peer countries and the savings are shown to Medicaid recipients.
For now, the deal is a commitment from pharma companies, a promise from the administration, and a question for Medicaid recipients.
The Peer Country Comparison
The GENEROUS model relies on prices available in peer countries. The reporting does not specify which countries or how those prices are calculated.
The model is designed to give states access to lower prices, but the source does not explain how the comparison is made or which countries are used as references.
The Companies Involved
The administration did not name all of the pharma companies that signed on to the model in its announcement. The source does not list individual companies or their specific commitments.
The agreement covers more than two dozen companies, each committing to sell drugs to state Medicaid programs at prices available in peer countries.
The Timeline So Far
| Date | Event |
|---|---|
| Friday | Trump announces all 50 states, Washington, D.C., and Puerto Rico will participate in the GENEROUS model |
| Prior to Friday | More than two dozen phara companies agree to sell drugs at prices available in peer countries |
The announcement Friday was the first public confirmation of nationwide participation. The timeline shows that the agreements were secured before the announcement, though the source does not give a specific date for when the deals were finalized.
The Open Questions
- How much money will states or patients actually see in their pockets?
- Which peer countries are used for price comparisons?
- How will the savings be measured and reported?
These questions remain unanswered as of Friday’s announcement. The administration has not provided answers to any of them.
The Reporting’s Limits
The reporting notes that the announcement left many questions unanswered. It does not attribute the observation to any named critic or group.
The reporting itself is limited to what was announced, and the source does not include additional commentary beyond the announcement’s framing.
The Bottom Line
The GENEROUS model is a central piece of Trump’s plan to lower drug prices. The administration has committed to giving states access to lower prices, but the details of how that works remain unclear.
The announcement was a statement of intent, not a statement of results. The proof will come when the prices are compared to those in peer countries and the savings are shown to Medicaid recipients.
For now, the deal stands as a promise from the administration and a question for Medicaid recipients.
Where the paper stands
The paper backs smaller government and is against agencies writing their own authority, especially when it comes to controlling private life, so it is against the administration’s model that hands over control to Washington rather than letting states decide for themselves. The GENEROUS model, which relies on pharma companies agreeing to sell drugs at prices available in peer countries, moves decision-making from the states to the federal level.
That shift concentrates power in one place. The administration has not answered basic questions about how much Medicaid recipients will save or which peer countries set the prices. The paper wants transparency, not promises without numbers.
What matters most is who holds the power. When the federal government writes its own rules and dictates prices across 50 states, it takes control away from the people who live there. The paper supports a system where states make their own deals with pharma companies, not one where Washington tells them what they can charge. The reader should watch for whether the administration ever answers the open questions it raised on Friday.
See the a run of 34 images at STAT.
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.